Reproductive Capacity and Iron Burden in Thalassemia
Completed · Not applicable
Conditions studied: THALASSEMIA MAJOR
In brief
The improved long-term survival of thalassemia major (TM) patients has resulted in increased focus on the ability to preserve fertility. While the association of iron toxicity with vital organ dysfunction, heart and liver, has been extensively investigated, the correlation of reproductive capacity and extent of iron overload is not well understood. Despite remarkable progress in methodology for prediction of reproductive status and intervention for preserving fertility, implementation in thalassemia is lacking. The investigators hypothesize that iron toxicity to the anterior pituitary occurring in the process of transfusional iron loading is directly associated with a decline in gonadal function. The investigators expect pituitary MRI measurements of iron deposition as well as markers of oxidative damage to correlate with the functional studies of pituitary-gonadal axis performed in this study. This cross sectional study will examine the relation of pituitary iron deposition and pituitary volume; serum iron and oxidative stress measures, liver iron concentration (LIC), cardiac iron and chelation adequacy with pituitary and gonadal reproductive hormone levels (and spermatogenesis in adult male patients), in order to better define the association of iron burden and chelation patterns with fertility potential, in thalassemia patients with iron overload. The study will assess whether the current chelation treatment regimens, in particular during the pubertal developmental age, are adequate for preserving fertility and could lead to improved chelation routines for preventing the high prevalence of compromised fertility. In addition, by utilizing state-of-the-art markers for fertility status, findings from this study may improve current methods for screening for hypogonadism and reproductive potential and allow earlier intervention. The investigators propose to examine 26-30 patients, 12 years and older, with measures of fertility potential, and correlate them to their current iron burden parameters and to the cumulative iron effect as indicated by past iron overload patterns and chelation history.
Key facts
- Study ID
- NCT02308904
- Run by
- UCSF Benioff Children's Hospital Oakland
- People needed
- 59
- Starts
- 2013-06-01
- Expected to finish
- 2020-09-01
- Last updated by the study team
- 2020-12-23
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Transfusion-dependent* females and males with thalassemia (any genotype) who are 12 to 45 years of age.
- History of at least 5 years of chronic transfusion (defined as ≥ 8 transfusions/year) (Age of initiation of transfusions does not matter)
- Any pubertal stage.
- Liver iron evaluated by SQUID, MRI or liver biopsy within 12 months prior to enrollment in the study.
- Need to be able to stop hormonal therapy for 3 weeks (males) and one month (females) prior to study enrollment.
You may not qualify if…
- Pregnant or lactating during study enrollment
- Unable to obtain liver iron concentration within 12 months prior or 6 months after study entry.
Where it is running
- UCSF Benioff Children's Hospital Oakland — Oakland, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.